



ADVISORY

Hydra Biosciences Presents “PAIN: a conversation”

Healthcare Leaders Discuss Need for Non-Addictive Options for Chronic Pain Treatment

October 20, 2015 – Cambridge, MA – [Hydra Biosciences](#), a leader in the field of Transient Receptor Potential (TRP) ion channel modulation, today announced the panelists for *PAIN: a conversation* featuring clinicians, scientists, patients and patient advocacy groups who will speak about the issues facing people with chronic pain on Thurs., Oct. 22, 6-9 p.m. at The Liberty Hotel in Boston.

What: *PAIN: a conversation* will address the need for new, innovative treatment options for patients with chronic pain and how, through the support of scientific innovation, the biotech and pharmaceutical industry, academic researchers, clinicians and patients, as well as political leaders and legislators can begin to address this significant unmet need.

When: Thurs., Oct. 22, 6-9 p.m.

Where: The Liberty Hotel in Boston.

Who: Panelists include:

- **Cheryl Bartlett**, Executive Director of the Cape Cod Regional Substance Abuse Prevention Initiative and Public Health at Cape Cod Health; former Commissioner of the state Department of Public Health
- **David Clapham**, Hydra founder, Chairman of the Hydra Scientific Advisory Board, Professor of Cardiology Children's Hospital Boston, Harvard Medical School, Howard Hughes Investigator
- **Russell Herndon**, CEO and President of Hydra Biosciences
- **Nathaniel Katz**, Neurologist and pain specialist; founder and president of Analgesic Solutions; professor at Tufts, formerly Harvard Medical School and Brigham and Women's Hospital
- **Cindy Steinberg**, National Director of Policy and Advocacy for the U.S. Pain Foundation; Policy Chair, Massachusetts Pain Initiative; Federal Appointee, Interagency Pain Research Coordinating Committee
- **Karen Meyers**, primary anchor for ABC6 in Providence and former anchor at New England Cable News and FOX5 in Washington, D.C., will moderate the discussion.

“I look forward to participating in a discussion that adds science and innovation to the ongoing statewide and national dialogue on the challenges of treating patients with severe pain and the opioid abuse epidemic,” said Ms. Bartlett, who often speaks on this issue locally and nationally given her past role as Massachusetts DPH Commissioner. “Having appeared on a number of panels focused on solving the problem of opioid addiction, this is the first that details how industry, science and innovation can play a role in addressing the need for non-opioid options for the treatment of chronic pain.”

PAIN: a conversation begins with a networking reception at 6 p.m. followed by the panel discussion at 7 p.m. Follow along on Twitter using #PAINconvo.

To register for the event, please email: llecain@lavoiehealthscience.com.

About Hydra Biosciences

Hydra Biosciences is a privately held biopharmaceutical company based in Cambridge, Massachusetts, that develops drugs to treat pain, inflammation, renal disease, anxiety and pulmonary disease using its expertise in novel ion channels. Hydra Biosciences' proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: www.hydrabiosciences.com. Follow us on [Twitter](#) and [LinkedIn](#).

###

Corporate:

Russell Herndon
Hydra Biosciences
617-494-5230 x3352

Media Contact:

Lindsay LeCain
LaVoieHealthScience
617-374-8800, Ext. 106
llecain@lavoiehealthscience.com